Ads
related to: monoclonal antibody treatment prostate cancer results today- Talk To Your Doctor
Review questions to start a
conversation with your doctor.
- Patient Resources
Download informative brochures for
patients and caregivers.
- Find An Imaging Site
Locate the nearest imaging site
or contact customer service.
- About Us
Understand how a PSMA PET scan may
help with your treatment plan.
- Talk To Your Doctor
Search results
Results from the WOW.Com Content Network
It binds to the epithelial cell adhesion molecule (EpCAM - CD326), with the intent to trigger antibody-dependent cellular cytotoxicity. It was developed by Micromet Inc, which was acquired by Amgen. [1] Adecatumumab has been used in clinical studies of treatment in colorectal, prostate [2] and breast cancers. [3] Phase II results were published ...
Abituzumab is a humanized IgG2 monoclonal antibody (mAb) targeted at CD51 (an integrin) currently in development by Merck KGaA Darmstadt, Germany in an attempt to prevent bone lesion metastases in castration-resistant prostate cancer. [1] [2]
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Leronlimab (codenamed PRO 140) is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system.It is being investigated as a potential therapy in the treatment of COVID-19, [1] [2] triple negative breast cancer, [3] and HIV infection. [4]
They then injected intact antibodies and demonstrated that CTLA-4 blockade enhanced T cell responses in mice responding to vaccines and to super antigens. [77] Leach, a new postdoctoral fellow, was tasked by Allison with applying these in tumor models. Antibody-treated mice showed significantly less cancer growth than the controls. [16]
It is a recombinant humanized monoclonal antibody of the immunoglobulin IgG1 subclass against the interleukin-6 receptor (IL-6R). [18] Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer.
Antibody-directed enzyme prodrug therapy (ADEPT) involves the application of cancer-associated monoclonal antibodies that are linked to a drug-activating enzyme. Systemic administration of a non-toxic agent results in the antibody's conversion to a toxic drug, resulting in a cytotoxic effect that can be targeted at malignant cells.
Capromab is a mouse monoclonal antibody which recognizes a protein found on both prostate cancer cells and normal prostate tissue. It is linked to pendetide , a derivative of DTPA . [ 2 ] Pendetide acts as a chelating agent for the radionuclide indium-111 .
Ads
related to: monoclonal antibody treatment prostate cancer results today